Introduction
IgA nephropathy (IgAN) is characterised by the deposition of IgA in the glomerular mesangium, and is among the most common forms of glomerulonephritis in developed countries 1 although most studies conclude that reduced galactosylation of some of the moieties is most likely 9, 10, 17, 18 . This leads to the hypothesis that reduced activity of the galactosylating enzyme C1Gal-T1 may be responsible, either due to some defect in the enzyme or its expression, or secondary to reduced availability of the chaperone protein Cosmc. In the haematological disorder Tn syndrome and in some cancers, a total lack of C1Gal-T1 activity in the affected clones results in undergalactosylation of the core 1 O-glycans of membrane proteins resulting in abnormal surface expression of the Tn antigen (GalNAc) 19 , an analogous situation to IgA1 in IgAN. In a Tn-expressing T cell line (Jurkat), the lack of C1Gal-T1 activity is due to a mutation in the Cosmc gene rather than in C1Gal-T1 itself 5 . Some support exists for both these . Therefore, changes in C1Gal-T1 or Cosmc activity are likely to be restricted to IgA1-producing B cells only.
Circulating B lymphocytes are mostly naïve or memory cells, and are not in the process of producing the secreted IgA1 molecules found in the serum and deposited in the kidney. Although the majority of IgA production normally occurs at mucosal sites, this does not appear to be the source of abnormal IgA1 production in IgAN.
Mesangial IgA1 in IgAN is polymeric: this type of IgA1 production is reduced in mucosal tissue in the patients 23, 24 , but increased in the bone marrow 25, 26 and tonsil 27 and these latter sites are therefore the most likely origin of pathogenic IgA1 molecules. Therefore, the aim of this study was to look for defects of Ogalactosylation factors which may account for abnormal IgA1 O-glycosylation in IgAN, focussing on the bone marrow. We directly measured B cell O-galactosylation activity effected by the galactosylating enzyme C1Gal-T1 with its molecular chaperone Cosmc. We also measured bone marrow C1Gal-T1 and Cosmc mRNA expression in relation to that of GalNAc-T2.
Results

Lectin binding of plasma IgA1
As is generally found in IgAN, serum IgA1 from patients had significantly higher
Helix aspersa (HA) lectin binding than did control IgA1 (mean A 492 HA/A 492 IgA1 ± SEM : IgAN 1.838±0.0397, control 1.562±0.0473, p=0.014).
Purity and yield of B cell preparations
Representative peripheral blood (PB) and bone marrow (BM) preparations were 89%
and 70% positive for the B cell surface marker CD22, and negative for T cell and monocyte markers (CD3, CD14). The lower percentage of B cells in BM is probably due to the earlier expression of CD19 (used for selection) than CD22 (used for detection) by B cell precursors: CD22-negative cells had the morphological appearance of immature lymphocytes. PB and BM B cell lysates with total protein concentrations of more than 100μg were obtained from all subjects.
C1Gal-T1/Cosmc O-galactosylation activity in PB and BM B cells
The O-galactosylation activity of PB and BM B cells in each subject is shown in Figures 3C and 3D ). Table 2 shows the gene expression ratios in patients with IgAN and controls. There was no difference between the subject groups in the ratios of C1Gal-T1:GalNAc-T2
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or C1Gal-T1:Cosmc in PB or BM lysates.
Correlation of enzyme gene expression with lectin binding of plasma IgA1 and
C1Gal-T1 activity
There was no correlation between the lectin binding of plasma IgA1 and the PB or BM gene expression ratios of C1Gal-T1:GalNAc-T2 or C1Gal-T1:Cosmc in either the IgAN or control groups (data not shown).
In the IgAN group only, B cell C1Gal-T1/Cosmc activity showed negative correlations with both C1Gal-T1:Cosmc Ct and C1Gal-T1:GalNAc-T2 ratios in PB and BM samples (Figure 4 ), although most of these did not reach statistical processing. In the controls, lectin binding showed a significant inverse correlation with enzyme activity in both PB and BM B cells. This is as expected, since the higher the O-galactosylation activity, the more galactosylated the O-glycans of IgA1 will be, and therefore the fewer ungalactosylated moieties will be available for HA binding.
This correlation supports the validity of the assays used in this study for both the enzyme activity and lectin binding. However, this inverse relationship was not seen in In IgAN PB cells, there was a significant negative correlation between the ratio C1Gal-T1:Cosmc and B cell O-galactosylation activity ( Figure 4A ). As Ct is inversely proportional to gene expression, this indicates that low enzyme activity may be associated with low C1Gal-T1 gene expression in relation to Cosmc; that is, either C1Gal-T1 is low or Cosmc is high. The same relationship was seen in the BM in IgAN, although this correlation did not reach statistical significance ( Figure 4B ). In both PB and BM, the ratio C1Gal-T1:GalNAc-T2 also showed a non-significant trend towards a negative correlation with C1Gal-T1 activity ( Figure 4C and D), suggesting that C1Gal-T1 expression is low in relation to GalNAc-T2. Although these correlations were not statistically significant, their consistent pattern suggests to us that they may indicate a biologically significant imbalance in C1Gal-T1 expression compared to the other two genes. As the ratio of Cosmc:GalNAcT-2 did not correlate with C1Gal-T1 expression at all, relatively low C1Gal-T1 expression rather than raised Cosmc or GalNAc-T2 expression is most likely to underlie the above correlations.
The results of this study show no absolute deficiency in B cell C1Gal-T1/Cosmc- 
Methods
Materials
Unless otherwise stated, all consumables were from Sigma Chemical Co, Poole, UK.
Subjects and samples
Twelve patients with IgAN (10 males, median age 39 years, range 29 to 69; details shown in Table 3 ) and 13 matched controls undergoing elective orthopaedic surgery (7 males, median age 37 years, range 17 to 75) were recruited. All patients had biopsy-proven IgA nephropathy with microscopic haematuria and/or proteinuria less than 1.4g/24h. At the time of the study no subject had an intercurrent illness, and none of the IgAN patients had macroscopic haematuria. The median serum creatinine in the IgAN patients was 105 μmol/l (range 58-162) and the median time from renal biopsy was 3 years (range 0. [5] [6] [7] [8] . No subject was receiving immunosuppressive treatments at the time of the study or in the previous 24 months. Bone marrow aspirates from the posterior iliac crest and 60ml of venous blood were collected at the same time. The study was approved by the LNR Research Ethics Committee and all subjects gave written informed consent.
IgA1 lectin binding
The binding of the O-glycan specific lectin Helix aspersa (HA) to plasma IgA1 was measured by modified ELISA exactly as we have previously described 22 . All samples were run in a single assay to allow direct comparison.
Preparation of B cell lysates for C1Gal-T1 assay
Plasma was separated from the blood samples and stored at -80°C until required, and (ATCC CRL 1593), were used as a standard and an internal control in the C1Gal-T1
assay. These were maintained in standard culture conditions in CM as above, feeding and passaging as necessary for consistent, healthy cell growth. When required for the assay, the cells were washed in protein-free HBSS and lysed in 2% Triton X 100/TBS.
The total protein concentration of the B cell lysates was measured using a commercial kit (DC Protein Assay, Bio-Rad, Hemel Hempstead, UK) according to the manufacturer's instructions.
Preparation of asialo-ovine submaxillary mucin acceptor for C1Gal-T1/Cosmc assay
Sialyl-OSM (sOSM) (derived from homogenised sheep submaxillary salivary glands) was kindly donated by Dr Tony Corfield, University of Bristol, UK. Desialylation was achieved by three sequential mild acid hydrolyses in 0.1M HCl at 80°C, followed by neutralisation with 1M NaOH. After dialysing against ultrapure water, the acceptor was lyophilised and stored at 4°C. This acceptor preparation was evaluated against an equivalent prepared, characterised and routinely used by Dr Corfield, and was shown to perform satisfactorily in preliminary assays, the two acceptors incorporating equivalent amounts of ( 14 C)Gal when incubated with the same lysate samples.
C1Gal-T1/Cosmc assay
The O-galactosylation activity measured in this assay relies on the function of both Each test lysate sample was run in duplicate. A standard curve of 8 serial dilutions of U937 cell lysate, and internal controls of 3 dilutions of THP-1 lysate and one blank were also set up each time the assay was performed.
The U937 lysate protein was arbitrarily assigned an enzyme activity of 1 arbitrary unit/μg total protein (1AU/μg), and standard curves constructed from which the Ogalactosylation activity of both the test and the internal control lysates were read and expressed as AU/μg total lysate protein.
O-glycosyltransferase gene expression
RNA extraction and cDNA synthesis
Total cellular RNA was extracted from PB mononuclear cells and bone marrow aspirates using RNAqueous-4 PCR (Ambion, Austin TX, USA). The optional DNase 1 and DNase inactivation steps were included to remove any residual genomic DNA.
cDNA was synthsised from the RNA using Reverse Transcriptase System (Promega, Southampton, UK), using random primers.
Real time PCR
cDNA sequences were amplified in an MX4000 thermocycler (Stratagene, Amsterdam, Netherlands) using primers detailed in Each reaction was run in duplicate. The results were obtained as the threshold cycle (Ct) at which a standard fluorescence level (set to 0.1) was reached in each reaction.
The higher the expression of each gene in the original sample, the lower the cycle number at which this threshold is reached, or in other words, a high gene expression gives a low Ct value and vice versa. Results were expressed as ratios of the Ct values of the genes to one another. As GalNAc is the core sugar to which the Gal is subsequently added we expressed C1Gal-T1 in terms of GalNAc-T2 ie C1Gal-T1:GalNAc-T2. The activity of C1Gal-T1 requires the chaperone protein Cosmc and therefore we calculated the ratio C1Gal-T1:Cosmc. Figure 3C ) and bone marrow ( Figure 3D ) B cells. 
Statistical analysis
